Glycosylated Hemoglobin and Risk of Perioperative Major Cardiovascular Events in Diabetic Patients Undergoing Coronary Bypass Revascularization (HbA1c)

University Hospital Basel

Status

Completed

Conditions

Coronary Artery Bypass Graft

Diabetes Mellitus

Cardiovascular Event

Treatments

Procedure: Coronary Bypass Revascularization

Study type

Observational

Funder types

Other

Identifiers

NCT03590223

2017-02156 (ch17berdajs)

Details and patient eligibility

About

Glycosylated Hemoglobin (HbA1c) is considered as one of the best markers to assess the glycaemia treatment over a period of 3 to 4 months, and is considered as predictive marker for perioperative mortality and morbidity. The impact of the elevated HbA1c on the risk of perioperative major cardiovascular events in patients undergoing coronary bypass revascularization (by retrospective analysis of perioperative cardiovascular events and preoperative HbA1c) is evaluated.

Enrollment

589 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria